Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genetic Discrimination Bill May Reach Senate Floor Before July 4 Recess

This article was originally published in The Gray Sheet

Executive Summary

Senate Majority Leader Bill Frist (R-Tenn.) hopes to bring the "Genetic Information Nondiscrimination Act" (S 1053) to the floor during the last two weeks of June - before Medicare reform is taken up

You may also be interested in...



SACGHS Endorses Frist’s Genetic Nondiscrimination Act At First Meeting

Members of the Secretary's Advisory Committee on Genetics, Health & Society (SACGHS) are drafting a letter to HHS Secretary Tommy Thompson expressing the panel's support for the Senate's Genetic Information Nondiscrimination Act (S 1053)

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel